Pfizer launches human trials for coronavirus vaccine, aims for emergency use in September
Pfizer, in partnership with German pharmaceutical company BioNTech, became the latest company to launch human trials for a potential coronavirus vaccine Monday.
If all goes well, the companies hope their COVID-19 vaccine could be ready for emergency use in September, in time for what many predict will be a period of rejuvenated viral transmission (if it subsides at all in the U.S. between now and then). The normal caveats apply here — the quest for a vaccine is moving along at a pace never before seen, which means that some essential steps may be purposefully skipped in the process, and many experts believe that getting a vaccine in even 18 months, let alone later this year, is overly optimistic.
Pfizer and some other companies are using a genetic material known as messenger RNA to develop their vaccine that could possibly train cells to create a protein the coronavirus latches onto without making a person sick. With the protein in the body, a person's immune system could then reportedly produce antibodies ready to fight off a future infection. The good news is that this technology is reportedly more stable than traditional vaccines which use weakened virus strains, and it's faster to produce, hence Pfizer's ambitious timeline. The catch is that no RNA messenger vaccine has ever reached the market before.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In other coronavirus development news, the United Arab Emirates found that a "minimally invasive" treatment in which stem cells are turned into a mist to be inhaled has resulted in "favorable" outcomes for COVID-19 patients and could hit the market in three months if trials keep going well. Israel, meanwhile, said it has isolated a key coronavirus antibody that could possibly "neutralize" the virus in a patient's body.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The Week contest: Airport goodbyes
Puzzles and Quizzes
By The Week US Published
-
'We shouldn't be surprised that crypto is back'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
How the national debt affects your finances
Rachel Reeves has changed the rules, but why does that matter?
By Marc Shoffman, The Week UK Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published